SCHEMBL4619630

SCHEMBL4619630

[CH2]COc1ccccc1OCC

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.56
L3MBTL1 Q9Y468 8/20 0.53
MAPT P10636 3/20 0.53
NPSR1 Q6W5P4 1/20 0.53
GLA P06280 1/20 0.53
TDP1 Q9NUW8 2/20 0.50
CYP1A2 P05177 1/20 0.50
CYP2D6 P10635 1/20 0.50
CYP2C19 P33261 1/20 0.50
ALOX15 P16050 1/20 0.46
HTR1A P08908 1/20 0.44
ADRA1D P25100 1/20 0.44
ADRA1A P35348 1/20 0.44
ADRA1B P35368 1/20 0.44
KDM4E B2RXH2 1/20 0.43
RAB9A P51151 1/20 0.43
ATM Q13315 1/20 0.43
HPGD P15428 1/20 0.43
GAA P10253 1/20 0.43
HCRTR1 O43613 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9584860 0.87 KDM4E (0.46) ALDH1A1L3MBTL1MAPTNPSR1GLA
1,2-Diethoxybenzene SCHEMBL578986 0.87 ALDH1A1 (0.68) ALDH1A1L3MBTL1MAPTNPSR1GLA
1,2-Diethoxybenzene SCHEMBL29428929 0.87 ALDH1A1 (0.68) ALDH1A1L3MBTL1MAPTNPSR1GLA
SCHEMBL7330758 0.82 L3MBTL1 (0.60) ALDH1A1L3MBTL1MAPTNPSR1GLA
SCHEMBL9209498 0.82 CYP1A2 (0.47) ALDH1A1L3MBTL1MAPTNPSR1TDP1
SCHEMBL402370 0.81 CA1 (0.62) ALDH1A1L3MBTL1TDP1CYP1A2LMNA
SCHEMBL10997495 0.81 ALDH1A1 (0.56) ALDH1A1L3MBTL1MAPTNPSR1GLA
SCHEMBL11152823 0.80 L3MBTL1 (0.61) ALDH1A1L3MBTL1MAPTNPSR1GLA
SCHEMBL6536519 0.80 CYP1A2 (0.60) L3MBTL1MAPTNPSR1TDP1CYP1A2
1,2-Diethoxybenzene SCHEMBL8912901 0.80 ALDH1A1 (0.60) ALDH1A1L3MBTL1MAPTNPSR1GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080033207-A1 Preparation of R-5- (2-(2-Ethoxyphenoxyetylamino) -2-Methoxybenzen-Sulphonamide Hydrochloride of High Chemical LEK PHARMACEUTICALS D.D. (SI) 2008-02-07 US claimed
JP-2007517797-A 2007-07-05 JP claimed
CN-1902166-A Preparation of r-5-(2-(2-ethoxyphenoxyethylamino)propyl)-2-methoxybenzenesulphonamide hydrochloride of high chemical purity LEK PHARMACEUTICALS (SI) 2007-01-24 CN claimed
EP-1708990-A1 PREPARATION OF R-5-(2-(2-ETHOXYPHENOXYETHYLAMINO)PROPYL)-2-METHOXYBENZENESULPHONAMIDE HYDROCHLORIDE OF HIGH CHEMICAL PURITY LEK Pharmaceuticals D.D. (SI) 2006-10-11 EP claimed
WO-2005063702-A1 PREPARATION OF R-5-(2-(2-ETHOXYPHENOXYETYLAMINO)PROPYL)-2- METHOXYBENZENESULPHONAMIDE HYDROCHLORIDE OF HIGH CHEMICAL LEK PHARMACEUTICALS D.D. (CH) 2005-07-14 WO claimed
EP-0822814-A4 ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS MERCK & CO INC (US) 1998-12-09 EP claimed
EP-0822814-A1 ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS Merck & Co., Inc. (US) 1998-02-11 EP claimed
WO-1996032938-A1 ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 1996-10-24 WO claimed
CN-115232034-B Synthesis method of tamsulosin hydrochloride 上药康丽(常州)药业有限公司 2024-02-20 CN disclosed
WO-2022149081-A1 IMPROVED PROCESS FOR THE PREPARATION OF A COMPOUND USEFUL IN THE PREPARATION OF ANTI-ANDROGENIC COMPOUND OCIMUM LABS PRIVATE LIMITED (IN) 2022-07-14 WO disclosed
CN-103664538-A Method for preparing 2-(2-ethoxyphenoxy) ethyl bromide CHINA MEDICINE RES & DEV CT CO LTD 2014-03-26 CN disclosed
CN-100584826-C Preparation of r-5-(2-(2-ethoxyphenoxyethylamino)propyl)-2-methoxybenzenesulphonamide hydrochloride of high chemical purity LEK PHARMACEUTICALS 2010-01-27 CN disclosed
EP-1885692-A2 PROCESS FOR THE PREPARATION OF TAMSULOSIN Medichem, S.A. (ES) 2008-02-13 EP disclosed
US-20080033207-A1 Preparation of R-5- (2-(2-Ethoxyphenoxyetylamino) -2-Methoxybenzen-Sulphonamide Hydrochloride of High Chemical LEK PHARMACEUTICALS D.D. (SI) 2008-02-07 US disclosed
EP-0822814-A1 ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS Merck & Co., Inc. (US) 1998-02-11 EP disclosed
US-5668148-A BENIGN PROSTATIC HYPERTROPHY MERCK & CO., INC. (US) 1997-09-16 US disclosed
WO-1996032938-A1 ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 1996-10-24 WO disclosed
EP-0054132-B1 PYRIMIDONES, THEIR PREPARATION AND MEDICINES CONTAINING THEM Dr. Karl Thomae GmbH (DE) 1984-10-10 EP disclosed
US-4379788-A HYPOTENSIVES, ANTIARRHYTHMIA, B-BLOCKERS DR. KARL THOMAE GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1983-04-12 US disclosed
EP-0054132-A1 Pyrimidones, their preparation and medicines containing them Dr. Karl Thomae GmbH (DE) 1982-06-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080033207-A1 Preparation of R-5- (2-(2-Ethoxyphenoxyetylamino) -2-Methoxybenzen-Sulphonamide Hydrochloride of High Chemical ADRA2C, ADRB2, REN ALDH1A1 2115/4885L3MBTL1 4842/4885MAPT 3021/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.